Company intelligence / Profile preview
Bioprojet Biotech
Paris, Ile-de-France, Francebioprojet.com ↗
- Ownership
- Private
- Employees
- ~152
- Development stage
- Commercial
01
Overview
Bioprojet has successfully developed several "First in Class" drugs including racecadotril (enkephalinase inhibitor), pitolisant (H3 histamine receptor inverse agonist/antagonist), and BP1.4979 (partial agonist of D3 dopamine receptor). Their flagship product Wakix (pitolisant) is approved for narcolepsy treatment in Europe and the US, including for children over 6 years of age as of March 2023.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Harmony Biosciences (licensing agreement for pitolisant in the US)
Beyond the preview
Go deeper on Bioprojet Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioprojet Biotech.